Please ensure Javascript is enabled for purposes of website accessibility

Why Are Pfizer and Moderna Jacking Up COVID Vaccine Prices?

By Keith Speights and Brian Orelli, PhD – Aug 13, 2021 at 6:15AM

Key Points

  • Pfizer and Moderna have increased their COVID-19 vaccine pricing in recent EU deals, according to the Financial Times.
  • Continued strong demand and relatively limited supply for the vaccines paved the way for these price hikes.
  • Over the longer term, an increased supply of vaccines should cause prices to decline.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

We're seeing the laws of supply and demand at work.

Both Pfizer (PFE 0.73%) and Moderna (MRNA -0.58%) are increasing the prices they charge for their COVID-19 vaccines, according to a recent Financial Times report. In this Motley Fool Live video recorded on Aug. 4, Motley Fool contributors Keith Speights and Brian Orelli discuss why these companies are jacking up the prices for their COVID-19 vaccines.

10 stocks we like better than Pfizer
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

They just revealed what they believe are the ten best stocks for investors to buy right now... and Pfizer wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

 

*Stock Advisor returns as of August 9, 2021

 

Keith Speights: We talked about this briefly on Monday, Brian, but a Financial Times article said that Pfizer has increased its COVID-19 vaccine price by more than 25%, while Moderna has raised its vaccine price by more than 10%, and both of these are in recent EU supply deals.

Brian, what's going on here with these price hikes? Do you think the vaccines are likely to get more or less expensive over time?

Brian Orelli: It would seem this is just general supply and demand. The EU has a strong demand and the mRNA vaccine companies have a limited supply. When demand is strong and supply is low, then prices get raised.

It should be noted that while Pfizer took a bigger jump there on the percentage basis, it started reportedly at a lower base. The new figures still have Moderna getting more per shot than Pfizer's. The reported amounts were $25.50 for the Moderna now and $23.19 for Pfizer and BioNTech (BNTX 4.29%).

The price jump is certainly good news for the companies now, but I don't see how it's going to last long-term with so many other vaccines in development. They're definitely going to increase the supply as are the companies that have already gained Emergency Use Authorization and that should decrease the prices over time, if we are talking about using these vaccines in future years, 2023-2024 range.

Speights: No matter what products you're talking about, cars, TVs, computers, and vaccines, the laws of supply and demand do work over time.

Orelli: A lot of times for branded drugs, there's only one drug. Then the company doesn't have to be competing against anybody else. But once you start getting multiple companies that are selling drugs that are very similar, now there's some price competition between the two.

Speights: You and I were just talking about Novavax (NVAX 0.60%) getting a 200 million-dose supply deal with the European Union. The more doses that are available, the more price pressure there is.

I think the one dynamic to watch obviously is the variants here. While there's plenty of supply right now, if the vaccines that are currently available are rendered significantly less effective or ineffective against new variants that might emerge, then you have to erase the board. Because then it's a matter of which company can come out with a vaccine that is effective and you start right from scratch with the supply demand curve.

Orelli: Exactly.

Keith Speights owns shares of Pfizer. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Stock Quote
Pfizer
PFE
$49.57 (0.73%) $0.36
Novavax Stock Quote
Novavax
NVAX
$16.64 (0.60%) $0.10
Moderna Inc. Stock Quote
Moderna Inc.
MRNA
$175.38 (-0.58%) $-1.02
BioNTech SE Stock Quote
BioNTech SE
BNTX
$161.49 (4.29%) $6.64

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.